2-piperazino-5,6-dihydro-7-methyl-6-oxo(7H)pyrrolo[2,3-d]pyrimidine | 104966-19-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-piperazino-5,6-dihydro-7-methyl-6-oxo(7H)pyrrolo[2,3-d]pyrimidine
• 英文别名: 2-piperazino-7-methyl-6-oxo-5,6-dihydro(7H)pyrrolo[2,3-d]pyrimidine；5,6-Dihydro-7-methyl-6-oxo-2-piperazino(7H)pyrrolo[2,3-d]pyrimidine；2-piperazino-7-methyl-6-oxo-5,6-dihydro(7H)pyrro-[2,3-d]pyrimidine；2-piperazino-7-methyl-6-oxo-5,6-dihydro(7H)pyrro[2,3-d]pyrimidine；2-piperazino-5,6-dihydro-7-methyl-6-oxo(7H) pyrrolo[2,3-d]pyrimidine；7-methyl-2-piperazin-1-yl-5H-pyrrolo[2,3-d]pyrimidin-6-one
• CAS: 104966-19-0
• 化学式: C₁₁H₁₅N₅O
• 分子量: 233.273
• InChiKey: FKQOHYNALFPAIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  61.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-piperazino-5,6-dihydro-7-methyl-6-oxo(7H)pyrrolo[2,3-d]pyrimidine 生成 5,6-Dihydro-7-methyl-6-oxo-2-piperazino(7H)pyrrolo[2,3-d]pyrimidine phosphate
  参考文献：
  名称：

  AWAYA, AKIRA;NAKANO, TAKUO;KOBAYASHI, HISASHI;TAN, KEN E.;HORIKOMI, KAZUT+

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-Benzylpiperazino)-5,6-dihydro-7-methyl-6-oxo(7H)-pyrrolo[2,3-d]pyrimidine 生成 2-piperazino-5,6-dihydro-7-methyl-6-oxo(7H)pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  YOKOYAMA, KEIICHI;KATO, KOJI;KITAHARA, TAKUMI;OHNO, HIROYASU;NISHINA, TAK+

  摘要：

  DOI：

文献信息

• Therapeutic agent for neurological diseases
  申请人：Mitsui Petrochemical Industries Ltd.

  公开号：US04959368A1

  公开（公告）日：1990-09-25

  A pharmaceutical composition comprising a pyrimidine represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom, an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, an alkoxycarbonylmethyl group having 3 to 5 carbon atoms, a 3,4-dimethoxybenzoyl group or a 3,4-methylenedioxybenzyl group, R.sup.2 represents a hydrogen atom, an amino group, a monoalkylamino group having 1 to 4 carbon atoms, an alkoxy group having 1 to 5 carbon atoms or an alkoxycarbonyl group having 2 to 4 carbon atoms, R.sup.3 represents a hydrogen atom, an alkoxycarbonyl group having 2 to 4 carbon atoms, a dialkylaminocarbonyl group having 1 to 9 carbon atoms in each alkyl moiety, an alkoxy group having 1 to 5 carbon atoms, or a hydroxyethyl group, R.sup.2 and R.sup.3, together with the carbon atoms to which they are bonded, may form a 5- to 7-membered carbocyclic ring or a heterocyclic ring having N, O or S as the hetero atom, and R.sup.4 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an alkylthio group having 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof. The above active compound has activities of promoting growth of nerve cells, forming neurites, and restoring motor functions, and is useful as an agent for treating diseases of peripheral and central nerves.

  一种制药组合物，包括以下式表示的嘧啶 ##STR1## 其中 R.sup.1代表氢原子、具有2至4个碳原子的酰基、具有2至5个碳原子的烷氧羰基、具有3至5个碳原子的烷氧羰甲基基团、3,4-二甲氧基苯甲酰基团或3,4-亚甲二氧基苯甲基团，R.sup.2代表氢原子、氨基、具有1至4个碳原子的单烷基氨基、具有1至5个碳原子的烷氧基或具有2至4个碳原子的烷氧羰基，R.sup.3代表氢原子、具有2至4个碳原子的烷氧羰基、每个烷基部分具有1至9个碳原子的二烷基氨基羰基、具有1至5个碳原子的烷氧基或羟乙基基团，R.sup.2和R.sup.3以及它们结合的碳原子可能形成一个含有N、O或S作为杂原子的5至7成员碳环或杂环，R.sup.4代表氢原子、具有1至4个碳原子的烷基或具有1至4个碳原子的烷硫基，或其药用可接受盐。上述活性化合物具有促进神经细胞生长、形成神经突起和恢复运动功能的活性，并可用作治疗外周和中枢神经疾病的药物。
• Pyrimidines and pharmaceutically acceptable salts thereof useful in
  申请人：Mitsui Petrochemical Industries, Ltd.

  公开号：US05304555A1

  公开（公告）日：1994-04-19

  This invention provides novel pyrimidines or their pharmaceutically acceptable salts thereof and process for preparation thereof. The novel compounds are useful for neurological diseases of the peripheral and central nervous systems of animals.

  这项发明提供了新型嘧啶或其药用可接受的盐，以及其制备方法。这些新型化合物对动物的周围神经系统和中枢神经系统的神经病有用。
• AGENTS FOR TREATING NEUROPHATHY
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP0257102A1

  公开（公告）日：1988-03-02

  A medicinal composition comprising a pyrimidine compound represented by following general formula (I), wherein R' represents a hydrogen atom, an acyl group having 2 to 4 carbon atoms, an alkoxycarbonyl group having 2 to 5 carbon atoms, an alkoxycarbonylmethyl group having 3 to 5 carbon atoms a benzyl group, a 3,4-dimethoxybenzoyl group or a 3,4-methylenedioxybenzyl group; R2 represents a hydrogen atom, an amino group, a monoalkylamino group having 1 to 4 carbon atoms, an alkoxy group having 1 to 5 carbon atoms or an alkoxycarbonyl group having 2 to 4 carbon atoms; R3 represents a hydrogen atom, an alkoxycarbonyl group having 2 to 4 carbon atoms, a dialkylaminocarbonyl group having 1 to 9 carbon atoms in each alkyl moiety, an alkoxy group having 1 to 5 carbon atoms or a hydroxyethyl group, or R2 and R3 may be taken together to form a 4- to 7-membered carbocyclic or heterocyclic ring containing N, 0 or S as a hetero atom together with the carbon atom to which R2 and R3 ar bound: and R4 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an alkylthio group having 1 to 4 carbon atoms, or a pharmaceutically acceptable salt thereof is disclosed. These active compounds show activities of promoting growth of neural cells, forming neurites and restoring kinetic functions, thus being useful as agents for treating diseases of peripheral and central nerves.

  一种药物组合物，包含由以下通式(I)代表的嘧啶化合物，其中 R'代表氢原子、具有 2 至 4 个碳原子的酰基、具有 2 至 5 个碳原子的烷氧羰基、具有 3 至 5 个碳原子的烷氧羰甲基、苄基、3,4-二甲氧基苯甲酰基或 3,4-亚甲二氧基苄基；R2 代表氢原子、氨基、具有 1 至 4 个碳原子的单烷基氨基、具有 1 至 5 个碳原子的烷氧基或具有 2 至 4 个碳原子的烷氧羰基；R3 代表氢原子、具有 2 至 4 个碳原子的烷氧羰基、每个烷基中具有 1 至 9 个碳原子的二烷基氨基羰基、具有 1 至 5 个碳原子的烷氧基或羟乙基，或 R2 和 R3 可结合在一起形成 4 至 7 元碳环或杂环，其中 N、0 或 S 作为杂原子与 R2 和 R3 所结合的碳原子一起：和 R4 代表氢原子、1 至 4 个碳原子的烷基或 1 至 4 个碳原子的烷硫基，或其药学上可接受的盐。这些活性化合物具有促进神经细胞生长、形成神经元和恢复动力功能的活性，因此可作为治疗周围神经和中枢神经疾病的药物。
• Pyrimidines or their pharmaceutically acceptable salts thereof
  申请人：MITSUI PHARMACEUTICALS, INC.

  公开号：EP0305184A1

  公开（公告）日：1989-03-01

  Compounds of formula where X is -NR¹R² or SR⁴; Y is amino optionally substituted by alkyl; Z is methyl substituted by alkoxy carbonyl or alkoxycarbonyl or Y and Z together may form a divalent group -X-Y- of formula . The compounds are useful in the treatment if neurological diseases of the pheripheral and central nervous systems of animals.

  式中化合物 其中 X 是-NR¹R²或 SR⁴；Y 是任选被烷基取代的氨基；Z 是被烷氧羰基或烷氧羰基取代的甲基，或 Y 和 Z 可共同形成式中的二价基团-X-Y-。 .这些化合物可用于治疗动物外周和中枢神经系统的神经疾病。
• Wound-healing agent
  申请人：MITSUI PHARMACEUTICALS, INC.

  公开号：EP0743066A2

  公开（公告）日：1996-11-20

  The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or modification of biological activities of a growth and/or differentiation factor, a growth hormone or a cytokine. This invention also provides a wound-healing agent, which comprises as an active ingredient a compound of the following formula (1) or formula (2).

  本发明提供了一种筛选伤口愈合剂的方法，该方法包括根据生长和/或分化因子、生长激素或细胞因子的生物活性的增强或改变来确定一种物质作为伤口愈合剂的活性。本发明还提供了一种伤口愈合剂，其活性成分包括下式（1）或式（2）的化合物。